

Oncology Center of Excellence

Project Pragmatica:

Exploring Ways to Promote Efficient, Patient-Centric Drug Development for Patients with Rare Cancers

FDA Rare Disease Day 2024

Martha Donoghue, MD Associate Director, Pediatric Oncology and Rare Cancers Oncology Center of Excellence

OCE's Project Pragmatica



Problem: Traditional clinical trials can sometimes be complex & burdensome



Solution: Explore appropriate use of pragmatic design elements in clinical trials for *approved* oncology medical products

Current State



Complex and Restrictive

Resource Intensive



Highly Burdensome

- Patients
- Providers

FDA

Future State



8 More streamlined and generalizable

Targeted Objective-focused Approaches


Closer to Routine Care

- Increased Access
- Appropriate Flexibilities


OCE Project Pragamatica

Objective


Advancing evidence generation for approved oncology medical products by exploring innovative trial design approaches that introduce functional efficiencies and patient centricity through integration with real-world routine clinical practice.



PRAGMATICA LUNG TRIAL S2302 DESIGN



FDA




ENHANCING GENERALIZABILITY



Clinical Trials

Real World US Population







Envision the Future



Clinical Practice

Point of Care

Clinical Research



Acknowledgements

- OCE Leadership
 - Richard Pazdur
 - Paul Kluetz
 - Marc Theoret
 - Tamy Kim
- Project Pragmatica Leadership
 - Paul Kluetz
 - Donna Rivera
 - Harpreet Singh
 - Timil Patel



Oncology Center of Excellence

Thank you to patients, families, and caregivers for all you do to support development of new treatments for patients with cancer.